			.	XX 7 1		Immuno- modulatory treatment	MS type	Ambulation status	Manual dexterity	Cognition	Mood
	Age	Sex	Living situation	Work status							
					Education						
Age		.06	.04	04	01	.09	.38**	.35**	.19**	.26**	09
Sex	.06		.11	.00	-09	.10	06	.03	11	13	.05
Living situation	.04	.11		07	05	.05	.06	.08	.09	.01	.06
Work status	04	.00	07		.06	05	.03	.13*	07	.02	.10
Education	01	-09	05	.06		.05	.00	.10	.08	.20**	01
Immunomodulatory	.09	.10	.05	05	.05		.05	.16**	.18**	.14	08
treatment	.07	.10	.05	05	.05		.05	.10	.10	.14	00
MS type	.38**	06	.06	.03	.00	.05		.55**	.49**	.44**	.00
Ambulation status	.35**	.03	.08	.13*	.10	.16**	.55**		.54**	.42**	.04
Manual dexterity	.19**	11	.09	07	.08	.18**	.49**	.54**		.35**	02
Cognition	.26**	13*	.01	.02	.20**	.14	.44**	.42**	.35**		.02
Mood	09	.05	.06	.10	01	08	.00	.04	02	.02	

Supplementary material 1. Intercorrelation reported as Spearman's correlation coefficient for people with MS, between personal and MS-related variables, and variables reflecting functioning.

MS: multiple sclerosis.

**Correlation is significant at the 0.01 level.

*Correlation is significant at the 0.05 level.